DIGOXIN IS ASSOCIATED WITH IMPROVED TRANSPLANT-FREE INTERSTAGE SURVIVAL IN HIGH-RISK BUT NOT LOW-RISK PATIENTS WITH HYPOPLASTIC LEFT HEART SYNDROME (HLHS)

Digoxin use has been associated with lower interstage mortality in infants with HLHS and variants. The NEONATE score was developed to risk stratify patients for interstage mortality or transplantation; risk factors included type of stage 1 palliation (S1P)—Norwood with BT or Sano shunt vs. Hybrid